

## Product Datasheet

### Anti-ATF2 (Thr52)

 **Pooled Serum**


#### Overview

---

<b>Catalog #</b>	p115-52
<b>Host Species</b>	Rabbit Polyclonal
<b>Format</b>	Antigen Affinity Purified from Pooled Serum
<b>Applications</b>	WB 1:250
<b>Species Tested</b>	Human, Mouse
<b>Immunogen</b>	Synthetic phospho-peptide corresponding to amino acid residues surrounding Thr52 of human ATF2, conjugated to keyhole limpet hemocyanin (KLH).
<b>Molecular Weight</b>	74 kDa
<b>Cite this Antibody</b>	PhosphoSolutions Cat# p115-52, RRID:AB_2492045

#### Images

---



Western blot of UACC903 melanoma cell line lysate (DMSO) showing specific immunolabeling of the ~ 72 kDa ATF2 protein phosphorylated at Thr<sup>52</sup>. Immunolabeling is reduced by treatment of the lysate with the PKC catalytic inhibitor Gö6850.

Image courtesy of Eric Lau and Ze'ev Ronai.

## Details

---

<b>Target Description</b>	The transcription factor ATF2 is a member of the ATF/CREB family of leucine zipper proteins. In response to stress stimuli, it activates a variety of gene targets that are involved in oncogenesis, and has been correlated with maintenance of a cancer cell phenotype (Vlahopoulos et al., 2008). Inhibiting ATF2 impedes melanoma development and elicits tumor suppressor function (Bhoumik et al., 2008). To act as a tumor suppressor, ATF2 must localize at the mitochondria, and phosphorylation at Thr-52 by PKC $\epsilon$ regulates this translocation (Lau et al., 2012).
<b>Specificity</b>	Specific for endogenous levels of the ~72 kDa ATF2 protein phosphorylated at Thr52. Immunolabeling of the ATF2 band is reduced by treatment of the cells with the PKC catalytic inhibitor Gö6850.
<b>Production/Purification</b>	Prepared from rabbit serum by affinity purification via sequential chromatography on phospho and non-phosphopeptide affinity columns.
<b>Quality Control</b>	Western blots performed on each lot.
<b>Buffer</b>	10 mM HEPES (pH 7.5), 150 mM NaCl, 100 $\mu$ g per ml BSA and 50% glycerol.
<b>Storage</b>	Storage at -20°C is recommended, as aliquots may be taken without freeze/thawing due to presence of 50% glycerol.
<b>Stability</b>	After date of receipt, stable for at least 1 year at -20°C.

## Significant Citations

---

Kumar, V., Weng, Y.C., Wu, Y.C., Huang, Y.T. and Chou, W.H., 2018. PKC $\epsilon$  phosphorylation regulates the mitochondrial translocation of ATF2 in ischemia-induced neurodegeneration. *BMC neuroscience*, 19(1), p.76.

Lau, E., Sedy, J., Sander, C., Shaw, M.A., Feng, Y., Scortegagna, M., Claps, G., Robinson, S., Cheng, P., Srivas, R. and Soonthornvacharin, S., 2015. Transcriptional repression of IFN $\beta$ 1 by ATF2 confers melanoma resistance to therapy. *Oncogene*, 34(46), p.5739-48.

Varsano, T., Lau, E., Feng, Y., Garrido, M., Milan, L., Heynen-Genel, S., Hassig, C.A. & Ze'ev, A. R. (2013). Inhibition of melanoma growth by small molecules that promote the mitochondrial localization of ATF2. *Clinical Cancer Research*, 19(10), 2710-2722.

Lau, E., Kluger, H., Varsano, T., Lee, K., Scheffler, I., Rimm, D.L., Ideker, T. and Ze'ev, A.R., 2012. PKC $\epsilon$  promotes oncogenic functions of ATF2 in the nucleus while blocking its apoptotic function at mitochondria. *Cell*, 148(3), pp.543-555.

## Our Guarantee

---

As an original manufacturer, we are dedicated to creating quality and reproducible antibodies that further your research. We provide personalized customer support from the scientists that made the antibody and offer a free replacement or 100% refund if we cannot resolve an issue. Order today and experience **Antibodies that Work™**.

**Note:** For research use only. Not intended for therapeutic or diagnostic use. Use of all products is subject to our terms and conditions, viewable on our website.